Pharmaceuticals
Five V backs Australia radioactive drug maker
Australia’s Five V Capital has confirmed an investment of undisclosed size in Cyclotek, a radioactive drug maker positioning itself as part of an industry transition toward personalized medicine.
Polaris leads $27m round for Singapore's Engine Biosciences
US healthcare and life sciences growth investor Polaris Partners has led a USD 27m Series A round for Singapore-based cancer medicine developer Engine Biosciences.
East targets $30m for Indonesia healthcare VC fund
East Ventures has launched a dedicated Indonesia healthcare innovation fund with a target of USD 30m.
China's Atom Bioscience raises $83m
Chinese inflammatory and metabolic disease drug developer Atom Bioscience has raised USD 83m in Series D funding led by local biotech specialist Kaitai Capital.
Matrix, HongShan back China's Qihan Biotech
Matrix Partners China and HongShan (formerly Sequioa Capital China) have joined a USD 16m pre-Series B round for Qihan Biotech, a genome editing player active in human and agricultural therapies.
China's Lynk Pharmaceutical increases Series C to $44m
China-based drug developer Lynk Pharmaceuticals has closed a second tranche of Series C funding, taking the overall size of the round to CNY 322m (USD 44m).
China's Canton Biologics raises $41m Series C
Chinese pharmaceutical industry services provider Canton Biologics has completed a CNY 300m (USD 41m) Series C round led by state-owned SDIC Venture Capital.
Innovation can end China's healthcare downcycle - AVCJ Forum
Investors in Chinese healthcare are looking for innovators with global competencies to lead an industry recovery following a challenging past 12 months, the AVCJ Private Equity & Venture Forum China 2023 heard.
CICC leads $60m Series B for China's Grit Biotechnology
CICC Capital had led a USD 60m Series B round for Grit Biotechnology, a Shanghai-based drug developer that is working on pioneering cancer treatments involving tumour-infiltrating lymphocytes (LIT).
Qiming, Orbimed lead Series A for China's Epigenic
Qiming Venture Partners and OrbiMed Asia Partners have led a USD 32m Series A round for Chinese gene editing therapy start-up Epigenic Therapeutics.
The innovation game: China GPs play safe
China investors have abandoned their previous high-risk-high-return approach in favour of proven business models and profitability. Hotspots like autonomous driving, biotech, and SaaS are no exception
China's Leadsynbio raises Series D
Chinese synthetic biology company Leadsynbio has raised a Series D round of unspecified size from existing investors Lilly Asia Ventures and Sherpa Healthcare Partners.
China's Neurophth Biotechnology gets $97m Series C extension
Neurophth Biotechnology, a China-based gene therapy developer specialising in ocular diseases, has raised nearly CNY 700m (USD 97m) in an extended Series C round.
Japan's Miyako targets $140m for third VC fund
Japan’s Miyako Capital, an independent VC firm affiliated with Kyoto University, has launched its third deep tech fund with a target of JPY 20bn (USD 140.2m).
PE-owned Japanese drug maker seeks bankruptcy protection
Kyowa Pharmaceutical Industry, a Japanese generic drug manufacturer owned by Unison Capital, has applied for alternative dispute resolution, an out-of-court process that allows companies to continue operations while negotiating with creditors on a restructuring.
Singapore's Mirxes raises $50m, files for Hong Kong IPO
Singapore-based biotech player Mirxes has raised USD 50m in Series D funding - at a post-money valuation of USD 600m - from the likes of Beijing-based Fupu Capital and Japan's Mitsui & Co, and filed to list in Hong Kong.
Hong Kong's Immuno Cure raises $27m
Hong Kong’s Immuno Cure BioTech, a vaccine and antibodies developer focused on cancers, inflammatory and infectious diseases, has raised USD 27m in Series A funding featuring Gobi Partners.
China’s VectorBuilder becomes unicorn, files for Shanghai IPO
China-based gene delivery technology player VectorBuilder has topped up its Series C round - achieving unicorn status in the process - and filed for an IPO on Shanghai’s Star Market.
Legend Capital leads Series A for China CDMO CoJourney
China and US-based contract development and manufacturing organisation (CDMO) CoJourney has raised a Series A of USD 30m led by Legend Capital.
SDIC leads $97m Series A for China's Pyrotech Therapeutics
China-based Pyrotech Therapeutics, which develops treatments for inflammation and tumours, has raised a Series A of CNY 700m (USD 97m) led by state-owned investor SDIC Venture Capital.
Singapore T-cell therapist gets China government funding
Singaporean T-cell immunotherapy company Lion TCR has raised USD 40m in its second tranche of Series B funding. Guangzhou Industrial Investment and Capital Operation Holding Group led the round.
Bain buys Indian industrial chemicals business
Bain Capital has acquired India’s Porus Labs, a manufacturer of agricultural and speciality chemicals, including pharmaceutical industry ingredients.
PAG invests $200m in India's RK Pharma
PAG has invested USD 200m in RK Pharma, a US-headquartered generic drug maker with significant operations in India.
Kazakhstan investor backs TVM SE Asia healthcare fund
Qazaqstan Investment Corporation (QIC), a private equity fund-of-funds set up by the Kazakhstan government, has invested in a Southeast Asia fund managed by TVM Capital Healthcare.